Aα-Val360: A marker of neutrophil elastase and COPD disease activity

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 31-38

  Carter, Richard I ^a   Ungurs, Michael J ^a   Mumford, Richard A ^c   Stockley, Robert A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c Mumford Pharma Consulting   (United States)

Author keywords

Aetiology; Chronic obstructive pulmonary disease; Disease progression; Leukocyte elastase

Indexed keywords

ALANINEALPHA VALINE; ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; LEUKOCYTE ELASTASE; UNCLASSIFIED DRUG; FIBRINOGEN; FIBRINOGEN AALPHA; PEPTIDE FRAGMENT;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FIBRINOGEN; HUMANS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

MLCS; MLOWN;

EID: 84872185953     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00197411     Document Type: Article

References (26)

1. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. 2010. http://guidance.nice.org.uk/CG101/Guidance/pdf/English Date last accessed: October 22, 2010. Date last updated: May 30, 2012.
2. Herpel LB, Kanner RE, Lee SM, et al. Variability of spirometry in chronic obstructive pulmonary disease: results from two clinical trials. Am J Respir Crit Care Med 2006; 173: 1106-1113.
3. Klein JS, Gamsu G,WebbWR, et al. High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity. Radiology 1992; 182: 817-821.
4. Parr DG, Stoel BC, Stolk J, et al. Validation of computed tomographic lung densitometry for monitoring emphysema in α1-antitrypsin deficiency. Thorax 2006; 61: 485-490.
5. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133: 1336-1343.
6. Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007; 62: 515-520.
7. US Food and Drug Administration. Clinical and Surrogate Endpoints for Evaluating Efficacy of α1-Proteinase Inhibitor (Human) Augmentation Therapy. 2009. www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ BloodProductsAdvisoryCommittee/UCM171091.pdf. Date last accessed: January 11, 2010.
8. Eriksson S. Studies in α1-antitrypsin deficiency. Acta Med Scand Suppl 1965; 432: 1-85.
9. Campbell EJ, Campbell MA, Boukedes SS, et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in α1-antitrypsin deficiency. J Clin Invest 1999; 104: 337-344.
10. Weiss ST, Segal MR, Sparrow D, et al. Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol 1995; 142: 493-498.
11. Sparrow D, Glynn RJ, Cohen M, et al. The relationship of the peripheral leukocyte count and cigarette smoking to pulmonary function among adult men. Chest 1984; 86: 383-386.
12. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-471.
13. Woolhouse IS, Bayley DL, Lalor P, et al. Endothelial interactions of neutrophils under flow in chronic obstructive pulmonary disease. Eur Respir J 2005; 25: 612-617.
14. Burnett D, Chamba A, Hill SL, et al. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987; 2: 1043-1046.
15. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005; 29: 23-32.
16. Carter RI, Mumford RA, Treonze KM, et al. The fibrinogen cleavage product A{α}-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 2011; 66: 686-691.
17. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965; 1: 775-779.
18. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
19. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
20. Bergin C, Muller N, Nichols DM, et al. The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986; 133: 541-546.
21. Stockley RA, Bayley DL. Validation of assays for inflammatory mediators in sputum. Eur Respir J 2000; 15: 778-781.
22. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests., European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
23. Cotes JE. Lung Function. Oxford, Blackwell Scientific Publications, 1975; pp. 384-386.
24. Weitz JI, Silverman EK, Thong B, et al. Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of α1-proteinase inhibitor. J Clin Invest 1992; 89: 766-773.
25. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32: 1146-1157.
26. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893-898.